Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Prevalence of MAFLD in Patients With Type 2 Diabetes in Jiangsu Province of China

Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

In 2019, the number of patients with diabetes was about 463 million in the world, accounting for 8.3% of the total population, and it is expected to rise to 578 million (9.2%) by 2030 and 700 million (9.6%) by 2045. According to the WHO diagnostic criteria, the prevalence of diabetes among adults in China from 2015 to 2017 was 11.2%, of which over 90% were type 2 diabetes mellitus (T2DM). The global prevalence of non-alcoholic fatty liver disease (NAFLD) is also very high, which was approximately 25% in 2016. The prevalence of NAFLD may continue to rise. NAFLD is often accompanied by clinical manifestations of metabolic syndrome, such as obesity, T2DM, hyperlipidemia and hypertension.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes - UAP were measured based on iLivTouch - Willing to attend this study and able to provide the written willing to sign a consent form. Who Should NOT Join This Trial: - Other types of diabetes - Patients unable to receive regular follow-up Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosed as T2DM according to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes * UAP were measured based on iLivTouch * Willing to attend this study and able to provide the written informed consent. Exclusion Criteria: * Other types of diabetes * Patients unable to receive regular follow-up

Treatments Being Tested

PROCEDURE

Ultrasound attenuation parameter measurement, fasting blood glucose and fasting insulin determination

Eligible participants will receive ultrasound attenuation parameter with iLivTouch, fasting blood glucose and fasting insulin determination

Locations (1)

Zhongda Hospital, Medical School, Southeast University
Nanjing, Jiangsu, China